Incidence of initiating a new antihypertensive therapy or new class of antihypertensive therapy. Incidence rates for initiation are shown for (A) all patients, (B) patients without baseline antihypertensive therapy, and (C) patients with baseline antihypertensive therapy. For zanubrutinib vs ibrutinib all populations are P > .05; chi-square test.